Erratum: Correction to July/August 2010 cover caption (Molecular Pharmaceutics DOI: 10.1021/mp700148h);Induced disorder in protein-ligand complexes as a drug-design strategy

Molecular Pharmaceutics

Volumn 5, Issue 3, 2008, Pages 430-437

  Crespo, Alejandro ^a   Fernández, Ariel ^a,b  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bcr Abl kinase; C Kit kinase; Conformational entropy; Entropic penalty; Imatinib; Induced disorder; Kinase inhibitor; PD173955; Protein drug affinity

Indexed keywords

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BCR ABL PROTEIN; IMATINIB; STEM CELL FACTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; DRUG CONFORMATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTHALPY; ENTROPY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 46449120133     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1002784     Document Type: Erratum

References (35)

1. Liddington, R. C. Structural basis of protein-protein interactions. Methods Mol. Biol. 2004, 261, 3-14.
2. Fernandez, A.; Scheraga, H. A. Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc. Natl. Acad. Sci. USA 2003, 100, 113-118.
3. Fuxreiter, M.; Simon, I.; Friedrich, P.; Tompa, P. Preformed structural elements feature in partner recognition by intrinsically unstructured proteins. J. Mol. Biol. 2004, 338, 1015-1026.
4. Whitesides, G. M.; Krishnamurthy, V. M. Designing ligands to bind proteins. Q. Rev. Biophys. 2005, 38, 385-395.
5. Freire, E. A thermodynamic guide to affinity optimization of drug candidates. In Proteomics and protein-protein interactions: Biology, chemistry, bioinformatics, and drug design; Waksman, G., Ed.; Protein Reviews 3; Springer: New York, 2005; pp 291-307.
6. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromo-lecular receptors. Angew. Chem., Int. Ed. 2002, 41, 2644-2676.
7. Schindler, T.; Bornmann, W. G.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science 2000, 289, 1938-1942.
8. Garcia-Viloca, M.; Gao, J.; Karplus, M.; Truhlar, D. G. How enzymes work: Analysis by modern rate theory and computer simulations. Science 2004, 303, 186-195.
9. Chang, C. A.; Chen, W.; Gilson, M. K. Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci. USA 2007, 104, 1534-1539.
10. Frederick, K. K.; Marlow, M. S.; Valentine, K. G.; Wand, A. J. Conformational entropy in molecular recognition by proteins. Nature 2007, 448, 325-330.
11. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell 2002, 109, 275-282.
12. Schittenhelm, M. M.; Shiraga, S.; Schroeder, A.; Corbin, A. S.; Griffith, D.; Lee, F. Y.; Bokemeyer, C.; Deininger, M. W. N.; Druker, B. I; Heinrich, M. C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006, 66, 473-481.
13. D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108, 286-291.
14. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schinlder, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
15. Donato, N. J.; Talpaz, M. Clinical use of tyrosine kinase inhibitors: Therapy for chronic myelogenous leukemia and other cancers. Clin. Cancer Res. 2000, 6, 2965-2966.
16. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B.; Wilson, K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004, 279, 31655-31663.
17. Attoub, S.; Rivat, C.; Rodrigues, S.; Van Bocxlaer, S.; Bedin, M.; Bruyneel, E.; Louvet, C.; Kornprobst, M.; Andre, T.; Mareel, M.; Mester, J.; Gespach, C. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002, 62, 4879-4883.
18. Furitsu, T.; Tsujimura, T.; Tono, T.; Ikeda, H.; Kitayama, H.; Koshimizu, U.; Sugahara, H.; Butterfield, J. H.; Ashman, L. K.; Kanayama, Y.; Matsuzawa, Y.; Kitamura, Y.; Kanakura, Y. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 1993, 92, 1736-1744.
19. Nagata, H.; Worobec, A. S.; Oh, C. K.; Chowdhury, B. A.; Tannenbaum, S.; Suzuki, Y.; Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 1995, 92, 10560-10564.
20. Fernández, A.; Sanguino, A.; Peng, Z.; Crespo, A.; Ozturk, E.; Zhang, X.; Wang, S.; Bornmann, W.; Lopez-Berestein, G. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res. 2007, 67, 4028-4033.
21. Fabian, M. A.; Biggs, W. A.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgand, S.; Insko, D. E.; Insko, M. A.; Lai, A.; Lelias, J. M.; Mehta, S.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zirrankar, P. P.; Lockhart, D. A. A small moleculekinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
22. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M., Jr.; Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A. E.; Seabra, G.; Wong, K. F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D. H.; Schafmeister, C.; Ross W. S.; Kollman, P. A. AMBER 9; University of California: San Francisco, 2006.
23. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E., III; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. A. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 1995, 91, 1-41.
24. Case, D. A.; Cheatham, T. E., III; Darden, T. A.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C. L.; Wang, B.; Woods, R. The Amber biomolecular simulation programs. J. Comput. Chem. 2005, 26, 1668-1688.
25. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R., Jr.; Ferguson, D.; Pellmeyer, D. C.; Fox, T.; Cadwell, J. W.; Kollman, P. A. A second generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
26. Lee, M. R.; Duan, Y.; Kollman, P. A. Use of MM-PB-SA in estimating the free energies of proteins: Application to native, intermediates, and unfolded villin headpiece. Proteins: Struct., Funct., Genet. 2000, 39, 309-316.
27. Wang, J.; Morin, P.; Wang, W.; Kollman, P. A. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of Efavirenz by docking and MM-PBSA. J. Am. Chem. Soc. 2001, 123, 5221-5230.
28. Swanson, J. M. J.; Henchman, R. H.; McCammon, J. A. Revisiting free energy calculations: A theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys. J. 2004, 86, 67-74.
29. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
30. Andricioaei, I.; Karplus, M. On the calculation of entropy from covariance matrices of the atomic fluctuations. J. Chem. Phys. 2001, 115, 6289-6292.
31. Surjit, B.; Andrews, D. Q.; Beveridge, D. L. Induced fit and the entropy of structural adaptation in the complexation of CAP and 1-repressor with cognate DNA sequences. Biophys. J. 2005, 88, 3147-3157.
32. Harris, S. A.; Gavathiotis, E.; Searle, M. S.; Orozco, M.; Laughton, C. A. Coperativity in drug-DNA recognition: A molecular dynamics study. J. Am. Chem. Soc. 2001, 123, 12658-12663.
33. Li, J. J.; Johnson, D. S.; Sliskovic, D. R.; Roth, B. D. Contemporary drug synthesis; Wiley-Interscience: Hoboken, NJ, 2004; pp 32-33..
34. Corbin, A. S.; Griswold, I. J.; La Rosée, P.; Yee, K. W. H.; Heinrich, M. C.; Reimer, C. L.; Druker, B. J.; Deininger, M. W. N. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 2004, 104, 3754-3757.
35. Lee, D.; Zhao, X.; Zhang, F.; Eisenberg, E.; Greene, L. E. Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors. J. Cell Sci. 2005, 118, 4311-4321.